California State Teachers Retirement System purchased a new position in Bio-Path Holdings Inc. (NASDAQ:BPTH) during the second quarter, Holdings Channel reports. The firm purchased 174,138 shares of the company’s stock, valued at approximately $347,000. California State Teachers Retirement System owned 0.19% of Bio-Path Holdings as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Renaissance Technologies LLC raised its position in shares of Bio-Path Holdings by 44.5% in the first quarter. Renaissance Technologies LLC now owns 116,600 shares of the company’s stock worth $302,000 after buying an additional 35,900 shares during the period. Bank of New York Mellon Corp raised its position in shares of Bio-Path Holdings by 176.3% in the second quarter. Bank of New York Mellon Corp now owns 283,747 shares of the company’s stock valued at $565,000 after buying an additional 181,038 shares during the last quarter. Finally, Concert Wealth Management Inc. raised its position in shares of Bio-Path Holdings by 1.2% in the second quarter. Concert Wealth Management Inc. now owns 302,645 shares of the company’s stock valued at $602,000 after buying an additional 3,445 shares during the last quarter. Institutional investors and hedge funds own 20.50% of the company’s stock.
Shares of Bio-Path Holdings Inc. (NASDAQ:BPTH) traded down 3.33% on Friday, reaching $1.16. 114,432 shares of the company’s stock traded hands. The company has a 50 day moving average price of $1.38 and a 200 day moving average price of $2.02. Bio-Path Holdings Inc. has a 52 week low of $1.13 and a 52 week high of $3.19. The firm’s market capitalization is $110.95 million.
Bio-Path Holdings (NASDAQ:BPTH) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.02). On average, equities research analysts predict that Bio-Path Holdings Inc. will post ($0.05) earnings per share for the current fiscal year.
Several research analysts have weighed in on the stock. Rodman & Renshaw restated a “buy” rating on shares of Bio-Path Holdings in a research report on Monday, July 11th. Maxim Group lowered their target price on shares of Bio-Path Holdings from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th.
About Bio-Path Holdings
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Want to see what other hedge funds are holding BPTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Path Holdings Inc. (NASDAQ:BPTH).
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.